This review discusses the methodological challenges to the evaluation of advanced therapy
medicinal products (ATMPs) by the UK National Institute for Health and Care Excellence …

Advanced therapy medicinal products (ATMPs) are a dynamic and current topic for
healthcare systems, with new products progressing to market at an increasing rate. ATMPs …

Background Advanced therapy medicinal products (ATMPs) represent an important
cornerstone for innovation in healthcare. However, uncertainty on the value, the high …

Background Advanced therapy medicinal products (ATMPs) are beginning to reach
European markets, and questions are being asked about their value for patients and how …

Objectives Advanced therapy medicinal products (ATMPs) are highly innovative therapies.
Their costs and uncertain value claims have raised concerns among health technology …

Abstract Background The National Centre for Pharmacoeconomics (NCPE) is commissioned
by the Corporate Pharmaceutical Unit of the Health Service Executive (HSE-CPU) to assess …

Objectives The uncertainty in the cost-benefit of advanced therapy medicinal products
(ATMPs) is a current challenge for their reimbursement in health systems. This study aimed …

Objectives To evaluate the incremental value of new drugs across disease areas receiving
favourable coverage decisions by the UK's National Institute for Health and Care Excellence …

Advanced therapy medicinal products (ATMPs) are a heterogeneous class of medicinal
products that by offering the potential of cure represent a paradigm shift in the approach of …

Objectives Advanced therapy medicinal products (ATMPs) are drugs for human use for the
treatment of chronic, degenerative, or life-threatening diseases that are based on genes …